{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:59:06Z","timestamp":1792609146645,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,28]]},"DOI":"10.7759\/cureus.106038","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T22:00:11Z","timestamp":1774735211000},"source":"Crossref","is-referenced-by-count":1,"title":["THR-\u03b2 Agonists vs Incretin Therapies for Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Biopsy-Anchored Systematic Review With Grading of Recommendations Assessment, Development and Evaluation (GRADE) Certainty"],"prefix":"10.7759","author":[{"given":"Amirah A","family":"Alzaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed Z","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiman","family":"Aman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghala M","family":"Asiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mada H","family":"Al Jibril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodan","family":"Desoky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad A","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lujain","family":"Suhaqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A","family":"Alkhalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai Y","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud S","family":"Desoky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023, 79:1542-1556.","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"81","author":"European Association for the Study of the Liver (EASL)","year":"2024","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024, 81:492-542. 10.1016\/j.jhep.2024.04.031","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023, 77:1797-1835. 10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"ref5","unstructured":"Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis. Developing Drugs for Treatment. (2018). Accessed: March 12, 2018: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/noncirrhotic-nonalcoholic-steatohepatitis-li...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison SA","year":"2024","unstructured":"Harrison SA, Bedossa P, Guy CD, et al.. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024, 390:497-509. 10.1056\/NEJMoa2309000","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison SA","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, et al.. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019, 394:2012-2024. 10.1016\/S0140-6736(19)32517-6","journal-title":"Lancet"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison SA","year":"2023","unstructured":"Harrison SA, Taub R, Neff GW, et al.. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2023, 29:2919-2928. 10.1038\/s41591-023-02603-1","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome PN","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, et al.. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021, 384:1113-1124. 10.1056\/NEJMoa2028395","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-2099. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong MJ","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, et al.. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016, 387:679-690. 10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis","volume":"391","author":"Loomba R","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, et al.. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024, 391:299-310. 10.1056\/NEJMoa2401943","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar\u2011Gomez E","year":"2015","unstructured":"Vilar\u2011Gomez E, Martinez\u2011Perez Y, Calzadilla\u2011Bertot L, et al.. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015, 149:367-378.","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.575843","article-title":"Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis","volume":"11","author":"Dennis A","year":"2020","unstructured":"Dennis A, Kelly MD, Fernandes C, et al.. Correlations between MRI biomarkers PDFF and cT1 with histopathological features of non-alcoholic steatohepatitis. Front Endocrinol (Lausanne). 2020, 11:575843. 10.3389\/fendo.2020.575843","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner DE","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005, 41:1313-1321. 10.1002\/hep.20701","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1999.01377.x","article-title":"Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions","volume":"94","author":"Brunt EM","year":"1999","unstructured":"Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999, 94:2467-2474. 10.1111\/j.1572-0241.1999.01377.x","journal-title":"Am J Gastroenterol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu V","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A, et al.. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005, 128:1898-1906. 10.1053\/j.gastro.2005.03.084","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021, 10:89. 10.1186\/s13643-021-01626-4","journal-title":"Syst Rev"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt G","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al.. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011, 64:383-394. 10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"ref21","unstructured":"U.S. Food and Drug Administration (2024) REZDIFFRA (resmetirom) Prescribing Information. Silver Spring, MD. FDA. (2024). Accessed: October 25, 2025: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217785s000lbl.pdf."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference BA","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al.. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017, 38:2459-2472. 10.1093\/eurheartj\/ehx144","journal-title":"Eur Heart J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-2232. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff AM","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022, 387:205-216. 10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.04.025","article-title":"An individual patient data meta-analysis to determine cut-offs for and confounders of magnetic resonance elastography in NAFLD","volume":"79","author":"Liang JX","year":"2023","unstructured":"Liang JX, Ampuero J, Niu H, et al.. An individual patient data meta-analysis to determine cut-offs for and confounders of magnetic resonance elastography in NAFLD. J Hepatol. 2023, 79:340-351.","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.044","article-title":"Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis","volume":"75","author":"Selvaraj EA","year":"2021","unstructured":"Selvaraj EA, M\u00f3zes FE, Jayaswal AN, et al.. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. J Hepatol. 2021, 75:770-785. 10.1016\/j.jhep.2021.04.044","journal-title":"J Hepatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis","volume":"19","author":"Stine JG","year":"2021","unstructured":"Stine JG, Munaganuru N, Barnard A, et al.. Change in MRI-PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2021, 19:2274.e5-2283.e5. 10.1016\/j.cgh.2020.08.061","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref28","article-title":"Correlations between MRI PDFF and cT1 with histopathological features across the NAFLD-NASH spectrum","volume":"11","author":"Dennis A","year":"2020","unstructured":"Dennis A, Kelly MD, Fernandes C, et al.. Correlations between MRI PDFF and cT1 with histopathological features across the NAFLD-NASH spectrum. Frontiers. 2020, 11:575843.","journal-title":"Frontiers"},{"key":"ref29","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril JJ","year":"2023","unstructured":"Wattacheril JJ, Abdelmalek MF, Lim JK, et al.. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2023, 165:1099-1113.","journal-title":"Gastroenterology"},{"key":"ref30","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor, and firsocostat in NASH: a phase 2 randomized trial","volume":"78","author":"Alkhouri N","year":"2023","unstructured":"Alkhouri N, Herring R, Kabler H, et al.. Safety and efficacy of combination therapy with semaglutide, cilofexor, and firsocostat in NASH: a phase 2 randomized trial. J Hepatology. 2023, 78:626-639.","journal-title":"J Hepatology"},{"key":"ref31","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"8","author":"Harrison SA","year":"2023","unstructured":"Harrison SA, Frias JP, Neff G, et al.. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Gastroenterol Hepatol. 2023, 8:1061-1074.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref32","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal A","year":"2018","unstructured":"Sanyal A, Charles ED, Neuschwander\u2011Tetri BA, et al.. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet. 2018, 392:p2705-p2717.","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque SM","year":"2021","unstructured":"Francque SM, Bedossa P, Ratziu V, et al.. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021, 385:1547-1558. 10.1056\/NEJMoa2036205","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis: a 5-year prospective study","volume":"159","author":"Lassailly G","year":"2020","unstructured":"Lassailly G, Caiazzo R, Ntandja\u2011Wandji LC, et al.. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis: a 5-year prospective study. Gastroenterology. 2020, 159:1290-1301.","journal-title":"Gastroenterology"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.19569","article-title":"Association of bariatric surgery with long-term adverse liver outcomes and MACE in biopsy-proven fibrotic NASH","volume":"326","author":"Aminian A","year":"2021","unstructured":"Aminian A, Al\u2011Kurd A, Wilson R, et al.. Association of bariatric surgery with long-term adverse liver outcomes and MACE in biopsy-proven fibrotic NASH. JAMA. 2021, 326:2031-2042.","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli A","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez\u2011Land\u00f3 L, et al.. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022, 10:393-406.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref37","doi-asserted-by":"crossref","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis","volume":"50","author":"Bucher HC","year":"1997","unstructured":"Bucher HC, Guyatt GH, Griffith LE, et al.. The results of direct and indirect treatment comparisons in meta-analysis. J Clin Epidemiol. 1997, 50:683-691.","journal-title":"J Clin Epidemiol"},{"key":"ref38","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti G","year":"2010","unstructured":"Salanti G, Ades A, Ioannidis J. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2010, 64:163-171.","journal-title":"J Clin Epidemiol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-015-3949-z","article-title":"Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis","volume":"26","author":"Singh S","year":"2016","unstructured":"Singh S, Venkatesh SK, Loomba R, et al.. Magnetic resonance elastography for staging liver fibrosis in non-alcoholic fatty liver disease: a diagnostic accuracy systematic review and individual participant data pooled analysis. Eur Radiol. 2016, 26:1431-1440. 10.1007\/s00330-015-3949-z","journal-title":"Eur Radiol"},{"key":"ref40","article-title":"Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial","volume":"8","author":"Loomba R","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ, et al.. Semaglutide 2\u00b74 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023, 8:p511-p522.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/469550-thr--agonists-vs-incretin-therapies-for-noncirrhotic-metabolic-dysfunction-associated-steatohepatitis-mash-a-biopsy-anchored-systematic-review-with-grading-of-recommendations-assessment-development-and-evaluation-grade-certainty","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T22:00:14Z","timestamp":1774735214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/469550-thr--agonists-vs-incretin-therapies-for-noncirrhotic-metabolic-dysfunction-associated-steatohepatitis-mash-a-biopsy-anchored-systematic-review-with-grading-of-recommendations-assessment-development-and-evaluation-grade-certainty"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.106038","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,28]]}}}